3 Things You'll Want to Watch in Valeant Pharmaceuticals' Q2 Results
Good news from Valeant Pharmaceuticals (NYSE: VRX)?
That's what investors got the last time the drugmaker announced its quarterly results. Valeant posted a profit in the first quarter. Its balance sheet was improved. Heck, the company even raised its earnings guidance for the full year.
Valeant provides an update on its second-quarter performance on Aug. 8. Could more good news be on the way? Here are three things you'll want to watch in the company's results.
Source: Fool.com
Bausch Health Companies Inc. Stock
€5.30
-1.010%
Bausch Health Companies Inc. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 12 € there is potential for a 126.24% increase which would mean more than doubling the current price of 5.3 € for Bausch Health Companies Inc..
